BIND Biosciences closes $11 M Series C financing round

BIND Biosciences, Inc., a Cambridge, MA-based biopharmaceutical company developing targeted therapeutics capable of differential delivery and controlled drug exposure to diseased tissue, secured an $11m Series C financing.
The financing was led by DHK Investment, representing David H. Koch, with participation by all existing investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners and NanoDimension, as well as new private investors.
The proceeds of this financing will be used to advance BIND’s preclinical product pipeline to clinical trials and expand its product development capabilities.
BIND’s Medicinal Nanoengineering platform is based on a combinatorial technology that allows for precise engineering of optimally designed targeted nanoparticles that substantially increase the clinical efficacy and safety of existing and new therapeutics.  

Join the discussion